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Abstract
Objective: This study was designed to examine the relationship between shortened activated partial thromboplastin time
(APTT) and increased fibrinogen values with diabetes mellitus.
Methods: APTT, prothrombin time (PT), fibrinogen, fasting plasma glucose (FPG) and glycosylated hemoglobin A1c (HbA1c)
levels were measured in 1,300 patients. Patients were divided into three groups according to their HbA1c and FPG levels.
Results: When participants were grouped according to their HbA1c levels, we found significantly shorter APTT values
(26.965.6 s) and increased fibrinogen levels (3.1, 1.9–6.3 g/L) in the diabetes group when compared with the other two
groups. When participants were grouped according to their FPG levels, we found significantly shorter APTT values
(26.966.2 s) and increased fibrinogen levels (3.1, 1.8–6.2 g/L) in the diabetes group when compared with the euglycemic
group.
Conclusions: Shorter APTT and increased fibrinogen levels might be useful hemostatic markers in patients with diabetes
and in patients at high risk for diabetes.
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Introduction
Patients with diabetes mellitus have a high risk of atherothrom-
botic events. Many studies have shown a variety of diabetes
mellitus-related abnormalities in hemostasis and thrombosis [1,2].
Venous thrombosis has also been found to occur more frequently
in diabetics. Eighty percent of patients with diabetes mellitus die
due to thrombosis, and 75% of these deaths are due to
cardiovascular complications. The vascular endothelium is the
primary site of defense against thrombosis and is abnormal in
patients with diabetes mellitus [3].
Although modern coagulation diagnostic tests are becoming
more sophisticated, standard coagulation screening tests, such as
activated partial thromboplastin time (APTT) and prothrombin
time (PT), are still important basic examinations in clinical
laboratories. APTT is commonly used to test the intrinsic
coagulation pathway, where a prolonged APTT is a clinical
indicator of either a factor deficiency or the presence of
coagulation inhibitors [4]. Recent studies have also shown that
shortened APTTs may also reflect procoagulant imbalances with
increased levels of coagulation factors. Therefore, APTT can be
used to assess the risk of thromboembolic complications in patients
with diabetes mellitus [5,6].
Plasma fibrinogen levels influence thrombogenesis, blood
rheology, blood viscosity and platelet aggregation. Epidemiological
studies have found a significant association between fibrinogen
levels and insulin levels [7,8]. Markers of fibrinolysis are abnormal
in people with metabolic syndrome, and fibrinolytic dysfunction is
markedly increased in subjects with diabetes mellitus and
abdominal obesity [7,9]. In addition, chronic hyperglycemia and
tissue glycation have marked effects on fibrin structure, clot
generation and resistance to fibrinolysis [7].
In the past, the American Diabetes Association (ADA) did not
recommend the use of HbA1c assays in the diagnosis of diabetes
[10], principally because HbA1c assays were not standardized.
HbA1c assays are now highly standardized and an international
expert committee has recommended the use of HbA1c assays in
the diagnosis of diabetes with a threshold of $6.5%[10]. The
ADA has since concurred with this recommendation [10].
In the present study, we collected clinical data related to general
coagulation function, as well as FPG and HbA1c levels from
subjects during admission to hospital. Participants were divided
into three groups based on either HbA1c or FPG levels [10]. The
groups based on HbA1c levels were delineated as follows: normal
group (HbA1c, #5.6%); high-risk diabetic group (HbA1c, 5.7% to
6.4%) and diabetic group (HbA1c, $6.5%). The groups based on
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L), impaired fasting glucose group (IFG; FPG, 5.6 to 6.9 mmol/L)
and diabetic group (FPG, $7.0 mmol/L). The purposes of the
present study were to evaluate whether shortened APTTs and
increased fibrinogen levels are related to increased FPG and
HbA1c levels, and to assess the differences of APTT and
fibrinogen levels among the three groups.
Materials and Methods
Patients
Inclusion criteria. The study included 1,300 patients (817
men and 483 women; median age, 64 yr; range, 39–83 yr) who
were admitted to various clinical departments in the first affiliated
hospital of Zhejiang University between May 2009 and February
2010. They all underwent APTT, PT, fibrinogen, FPG and
HbA1c measurements. Medical diagnoses were obtained from the
registered hospital records, including 726 patients with type 2
diabetes diagnosed according to the 1998 World Health
Organization guidelines [11] (average duration of diabetes
mellitus, 9.6 yr; range, 2,25 yr) and 574 cases of patients with
other diseases, except those listed in the exclusion criteria.
Exclusion criteria. Hypercoagulable states is broadly defined
as encompassing two clinical situations: i) the presence of laboratory
abnormalities, such as thrombocytosis or antithrombin III
deficiency, or clinical conditions, such as cancer, pregnancy, or
the postoperative state, that have been considered to be associated
with an increased risk of thromboembolic complications
(prethrombotic states); and ii) recurrent thrombosis in patients
who have no recognizable predisposing factors (thrombosis-prone
patients) [12]. Patients were excluded if they had a past history of a
predisposition to hypercoagulability, including the following:
thrombocytosis; a history of venous thromboembolism; known
inherited coagulation disorders; cancer; pregnancy; recent surgery;
hyperthyroidism; or patients who were taking standard anti-
coagulant treatment with either coumarin derivatives or heparins
at the time of admission. Patients with type 1 diabetes and a body
mass index (BMI) equal or greater than 28 kg/m
2 [13] were also
excluded from the study.
Ethics statement
This study was approved by the ethics committee of the First
Affiliated Hospital of Medical college at Zhejiang University,
China, and was in accordance with the Helsinki declaration.
Written informed consent was obtained from each of the
participants at the time of enrollment.
Assays
All specimens for APTT, PT, fibrinogen, FPG and HbA1c
measurements were obtained by venepuncture in the morning
after a 12 h fast. APTT, PT and fibrinogen levels were measured
with the coagulation method on a Sysmex CA7000 System
(Sysmex, Kobe, Japan) using Dade Behring reagents (Dade-
Behring, Marburg, Germany). FPG was determined on an
Abbott Aeroset (Abbott Laboratories, Illinois, USA) using Roche
reagents (Roche Diagnostics, Indianapolis, USA). HbA1c was
determined on a Bio-Rad Variant II HbA1c analyzer (Bio-Rad,
California, USA). Our laboratory constructed our own reference
ranges for APTT, PT and fibrinogen, according to the CLSI
C28-A2 [14]. The reference ranges used were as follows: 22.0–
36.0 s for APTT; 10.5–14.0 s for PT; and 2.0–4.0 g/L for
fibrinogen. BMI as an index to estimate the extent of obesity was
calculated by body weight (kg) divided by the square of the height
(m
2) [13].
Statistics
Statistical analysis was carried out using SPSS, version 11.5. PT
and APTT results were normally distributed and were reported as
the mean 6 standard deviation. Fibrinogen levels, age and BMI
values were not normally distributed and were therefore reported
as the median 65
th -95
th percentile distribution. The significances
of the differences in PT and APTT between groups were
determined using a one way analysis of variance (ANOVA). The
significance of differences of fibrinogen, age and BMI between
groups were determined using the Mann-Whitney U test. The
significance of differences in sex, shortened PT, APTT and
increased fibrinogen between groups were compared with the Chi-
square test. All statistical tests were 2-tailed with p-values ,0.05
taken as significant.
Results
The sex, age, BMI, PT, APTT and fibrinogen levels of the study
participants were compared after they were grouped according to
HbA1c or FPG levels (Tables 1 and 2). There were no significant
differences in terms of sex, age and BMI differences among these
two sets of three groups. When the high-risk diabetic group was
compared with the normal group, statistically significant differ-
ences were observed in overall APTT (p=0.049), APTT ,22 s
(p=0.018) and fibrinogen levels (p=0.036). When the diabetic
group was compared with the normal group, statistically
significant differences were observed in overall APTT (p,0.001),
APTT ,22 s (p=0.001), PT (p=0.016), PT ,10.5 s (p=0.012),
fibrinogen levels (p,0.001) and fibrinogen .4.0 g/L (p=0.004).
When the diabetic group was compared with the high-risk diabetic
group, statistically significant differences were observed in the
overall APTT (p=0.041), fibrinogen levels (p,0.001) and
fibrinogen .4.0 g/L (p,0.001). We also found significantly
shortened APTT values (26.965.6 s) and increased fibrinogen
levels (3.1, 1.9–6.3 g/L) in the diabetic group than in the other two
groups. APTT ,22 s and fibrinogen .4.0 g/L were more
frequently observed in the diabetic group (16.2% and 27.2%,
respectively) than in the other two groups.
In terms of the three groups divided according to their FPG
values [10], when the IFG group was compared with the
euglycemic group, a statistically significant difference in overall
Table 1. APTT, PT and fibrinogen in patients grouped by
HbA1c levels.
HbA1c(%)
#5.6 5.7–6.4 $6.5
N 151 373 776
Age(years) 63(36–86) 63(42–83) 64(40–82)
Female/male 64/87 127/246 292/484
BMI(kg/m
2) 22.8(19.8–27.2) 23.1(20.1–27.3) 23.3(20.2–27.4)
APTT(s) 28.867.0 27.666.5* 26.965.6*g
APTT,22 s 9(6.0%) 49(13.3%)* 126(16.2%)*
PT(s) 11.761.3 11.561.4 11.461.5*
PT,10.5 s 13(8.6%) 57(15.3%) 163(21.0%)*
Fibrinogen(g/L) 2.7(1.6–5.3) 2.9(1.7–5.9)* 3.1(1.9–6.3)*g
Fibrinogen.4.0 g/L 24(15.9%) 63(16.9%) 211(27.2%)*g
*p,0.05 comparison with HbA1c#5.6%; g p,0.05 comparison with HbA1c
5.7–6.4%.
doi:10.1371/journal.pone.0016470.t001
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compared with the euglycemic group, significant differences were
observed in overall APTT (p=0.031), APTT ,22 s (p=0.003),
PT ,10.5 s (p,0.001), fibrinogen levels (p=0.002) and fibrinogen
.4.0 g/L (p=0.016). When the diabetic group was compared
with the IFG group, significant differences were noted only in PT
,10.5 s (p=0.046).
Discussion
Patients are considered to have a hypercoagulable state if they
have laboratory abnormalities or clinical conditions that are
associated with increased risk of thrombosis; diabetic patients meet
these criteria [12,15]. Hyperglycemia contributes to the hyperfi-
brinogenemia of diabetic patients and activates the coagulative
cascade, thus increasing thrombin formation and fibrinogen
degradation products, which may stimulate hepatic fibrinogen
synthesis [12,16]. Diabetic patients have elevated levels of
fibrinogen and factors in the intrinsic pathway, which are
determinants of APTT [6].
PT and APTT tests are standard screening tests for function of
the coagulation system and their utility in monitoring therapeutic
anticoagulation is widely accepted [17]. The APTT assay is
traditionally used for identifying abnormalities in the contact
(factor XII, prekallikrein, and high-molecular-weight kininogen),
intrinsic (factors XI, VIII, IX) and common (factors X, V and II
and fibrinogen) pathways of coagulation [5]. Prolonged APTT
values have clinical relevance as an indicator of factor deficiency
or the presence of coagulation inhibitors [4]. Shortened APTTs
are generally considered to be laboratory artifacts arising from
problematic venepunctures[18]. However, there is mounting
evidence that shortened APTT values in some cases may reflect
a hypercoaguable state, which is potentially associated with
increased thrombotic risk and adverse cardiovascular events
[4,6,16]. Shortened APTTs may result from an accumulation of
circulating activated coagulation factors in plasma caused by
enhanced coagulation activation in vivo [6,19].
The prothrombin time (PT) is the screening test for the
coagulation pathway initiated by tissue factor. PT is most sensitive
to factor VII (FVII) levels. Factor VII coagulant activity (FVII:c)
levels were higher in the type 2 diabetes patients and metabolic
syndrome individuals [7]. The activation of prothrombin occurs
on the platelet surface in vivo, the addition of platelets to plasma
and the activation of platelets accelerates the production of
thrombin [15]. When thrombin is formed from prothrombin,
prothrombin activation fragments 1 + 2 are released and these
levels are increased in diabetes [20].
Increased fibrinogen levels are a strong and independent
cardiovascular risk factor [16,20]. In a hyperglycemic environ-
ment, fibrinogen can become hyperglycosylated [15]. When this
abnormal fibrinogen clots, the resulting fibrin structure is
composed of small diameter fibers that are markedly resistant to
degradation by plasmin [15].
Shortened APTTs values are found with a prevalence of 2.5%–
5% in hospitalized patients [8,17]. In our study, whether patients
were grouped according to HbA1c or FPG levels, the APTT values
in the diabetic, high-risk diabetic or IFG groups were significantly
shorter than in the normal groups, and APTT values below the
reference range (APTT ,22 s) were more frequent. Additionally,
fibrinogen levels were significantly higher in the diabetic and high-
risk diabetic groups than in the normal group, and fibrinogen values
above the reference range (fibrinogen .4.0 g/L) were more
frequent in the diabetic groups. Therefore, the results of this study
clearly show that diabetic and high-risk diabetic patients have
shortened APTTs and elevated fibrinogen levels.
Lippi et al. [6] showed that IFG and diabetic groups had
significantly shortened APTT values and suggested that APTT
might identify diabetic patients at major risk of thrombosis. In
contrast, in our study, when patients were grouped by their HbA1c
levels, the APTT values of the diabetic group were significantly
shorter than the high risk group (Table 1); furthermore, when
patients were grouped according to FPG levels, the APTT and
fibrinogen values in patients with diabetes were not significantly
different than the IFG group (Table 2). The difference in the two
studies may be due to a lack of concordance between the HbA1c
and FPG tests. Analyses of data from the National Health and
Nutrition Examination Survey (NHANES) indicate that the
HbA1c threshold of $6.5% identifies one-third fewer cases of
undiagnosed diabetes than a fasting glucose cut-off point of
$7.0 mmol/l [10], which results in differences in study popula-
tions depending on the diagnosing tests. Additionally, HbA1c
levels incorporate contributions from both fasting and post-
prandial glucose, which suggests that it gives a better representa-
tion of glucose intolerance as a whole. HbA1c has a higher
reproducibility rate than FPG and has less intra-individual
variation [22]. Avignon et al. [23] recently demonstrated that
postprandial glucose concentrations correlated independently and
significantly with HbA1c in type 2 diabetic individuals, whereas
fasting plasma glucose levels did not. The variability of HbA1c
values is also considerably less than that of FPG levels, with day-to-
day within-person variance of ,2% for HbA1c but 12–15% for
FPG [22].
Fibrinogen levels have been shown to be elevated in type 2
diabetes mellitus patients and to predict the development of type 2
diabetes in healthy individuals [24]. A positive correlation between
plasma glucose and fibrinogen levels has been reported in large
epidemiological studies [25]. In 1990, Van Wersch et al. [26]
observed increased fibrinogen concentrations in diabetic patients
but no significant difference in comparison with the reference
group. Similarly to the results of Lippi et al. [6] and Rotterdam et
al. [27].Acang and Jalil [28] observed that there were significantly
higher fibrinogen levels, and shortened PT and APTT values, in
diabetic patients, especially in patients with long-term diabetes
with chronic complications, which are consistent with the results of
this study.
Table 2. APTT, PT and fibrinogen in patients grouped by FPG
levels.
FPG(mmol/L)
,5.6 5.6–6.9 $7.0
N 590 279 431
Age(years) 64(39–84) 63(39–83) 63(33–79)
Female/male 217/373 110/169 156/275
BMI(kg/m
2) 23.0(20.3–27.2) 23.3(19.8–27.2) 23.3(20.2–27.5)
APTT(s) 27.866.2 26.865.5* 26.966.2*
APTT,22 s 67(11.4%) 40(14.3%) 77(17.9%)*
PT(s) 11.561.4 11.461.3 11.461.5
PT,10.5 s 84(14.2%) 48(17.2%) 101(23.4%)*g
Fibrinogen(g/L) 3.0(1.8–5.9) 3.1(1.8–6.3) 3.1(1.8–6.2)*
Fibrinogen.4.0 g/L 117(19.8%) 68(24.3%) 113(26.2%)*
*p,0.05 comparison with FPG,5.6 mmol/L; g p,0.05 comparison with
FPG5.6–6.9 mmol/L.
doi:10.1371/journal.pone.0016470.t002
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a shortened APTT had potential value for the early diagnosis of
myocardial infarction among patients hospitalized for chest pain.
Korte et al. [29] also found that patients presenting with shortened
APTT values had increased thrombin generation, were in a
complex hypercoagulant state and were at increased risk for
thromboembolism. Tripodi et al. [5] found that hypercoagulability
detected by shortened APTT values was independently associated
with venous thromboembolism (VTE) and hypothesized that
shortened APTT could be considered as a risk marker for VTE.
While the clinical relationship between shortened APTT,
increased fibrinogen levels and the risk of venous thrombosis is
supported by current scientific literature, the exact biological
mechanisms of thrombosis in diabetics are likely to be multifac-
torial and incompletely understood as yet [6,30]. Many authors
have suggested that hemorheological disturbance is an important
factor in the development of vascular complications. Alao et al.
[31] showed elevated levels of total cholesterol, high density
lipoprotein (HDL), low density lipoprotein (LDL) and triglycerides
in patients with diabetes mellitus compared to non-diabetic
controls; in particular, elevated LDL was a major risk factor for
coronary artery thrombosis, which confirmed that patients with
diabetes mellitus were predisposed to dyslipidemia, with higher
risks for vascular disorders. The hypercoagulable state has also
been suggested as a potential risk factor [28].
Endothelial abnormalities play a critical role in the enhanced
activation of platelets and clotting factors that occur in diabetic
patients. In such patients, coagulation activation markers are
elevated and coagulation abnormalities seem to be directly linked
to hyperglycemia, involving all stages of coagulation. Chronic
hyperglycemia results in hyperglycosylation of multiple proteins
[15]. The plasma levels of many clotting factors, including
fibrinogen, factor VII, factor VIII, factor XI, factor XII, kallikrein,
and von Willebrand factor are elevated in diabetes [6,15].
In summary, clinical tests for APTT and fibrinogen are
relatively inexpensive and are readily available. The results shown
in this study indicate that shortened APTT and increased
fibrinogen levels might be useful hemostatic markers in diabetic
patients, especially in those at high-risk for thrombotic complica-
tions. Further investigations of these markers could potentially be
used as screening tests for hypo- and hypercoaguable states that
are applicable to diabetes and other clinical conditions.
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